Picture of Hikma Pharmaceuticals logo

HIK Hikma Pharmaceuticals News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedLarge CapContrarian

REG - Hikma Pharmaceutical - Director/PDMR Shareholding <Origin Href="QuoteRef">HIK.L</Origin>

RNS Number : 8482W
Hikma Pharmaceuticals Plc
12 November 2014

Annex DTR3

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

All relevant boxes should be completed in block capital letters.

1.

Name of the issuer

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to

(i) a transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

(i) & (iii)





3.

Name of person discharging managerial

responsibilities/director

SAID DARWAZAH

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

N/A





5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial

interest 1

3 ABOVE

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

ORDINARY SHARES OF 10P EACH





7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

VIDACOS NOMINEES LIMITED

8.

State the nature of the transaction

SALE OF 155,724 ORDINARY SHARES





9.

Number of shares, debentures or financial

instruments relating to shares acquired

N/A

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

N/A





11.

Number of shares, debentures or financial

instruments relating to shares disposed

155,724

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

0.078%





13.

Price per share or value of transaction

19.006

14.

Date and place of transaction

10 to 12 NOVEMBER 2014, LONDON





15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

11,108,343 (5.67%) COMPRISING:

DIRECTLY: 190,000 (0.10%)

INDIRECTLY THROUGH DARHOLD LIMITED: 10,918,343 (5.51%)

16.

Date issuer informed of transaction

12 NOVEMBER 2014





If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

17.

Date of grant

N/A

18.

Period during which or date on which exercisable

N/A





19.

Total amount paid (if any) for grant of the option

N/A

20.

Description of shares or debentures involved (class and number)

N/A





21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

N/A

22.

Total number of shares or debentures over which options held following notification

N/A





23.

Any additional information

N/A

24.

Name of contact and telephone number for queries

PETER SPEIRS 0207 399 2772





Name of authorised official of issuer responsible for making notification

Peter Speirs, Company Secretary

Date of notification 12 November 2014

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.


This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSBDBDBDBBBGSD

Recent news on Hikma Pharmaceuticals

See all news